ABT
Abbott Laboratories
ABT has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ABT overall, supported by stronger fundamentals and stronger modeled upside.
ABT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Healthy | |
| Under pressure |
ABT's revenue and cash flow are currently healthy, and its profitability is stable, but its balance sheet is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $107 | — |
| Cheap | 22x | $58.67 | -45% |
| Fair | 33x | $88.57 | -17% |
| Current | 40x | $107 | — |
| Expensive | 45x | $121 | +13% |
Historical ranges are pointers, not guarantees.
ABT's PE is in its expensive range at 40x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ABT in the historical PE scenario, which offers more potential upside but is not a forecast.
ABT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for ABT, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ABT on the outlook, with more favorable profitability expectations.
ABT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.84 | +118% |
| Q3 2026 | $2.68 | -66% |
| Q2 2026 | $3.09 | -61% |
| Q1 2026 | $3.57 | -54% |
| Q4 2025 | $3.72 | -51% |
| Q3 2025 | $7.97 | +142% |
| Q2 2025 | $7.97 | +151% |
| Q1 2025 | $7.70 | +140% |
| Q4 2024 | $7.64 | +134% |
ABT's earnings per share have fallen from their peak: $2.68 over the past year, against $7.97 in mid-2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ABT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13B | +14% |
| Q2 2026 | $12.6B | +13% |
| Q1 2026 | $11.2B | +7.8% |
| Q4 2025 | $11.5B | +4.4% |
| Q3 2025 | $11.4B | +6.9% |
| Q2 2025 | $11.1B | +7.4% |
| Q1 2025 | $10.4B | +4% |
| Q4 2024 | $11B | +7.2% |
ABT's revenue has grown year over year for 12 quarters in a row: $13B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | -7.7 points |
| Q2 2026 | 13% | -5 points |
| Q1 2026 | 12% | -4.3 points |
| Q4 2025 | 20% | +2.2 points |
| Q3 2025 | 18% | +0.6 points |
| Q2 2025 | 18% | +2.3 points |
| Q1 2025 | 16% | +2.4 points |
| Q4 2024 | 17% | 0 points |
ABT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ABT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ABT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | -47% |
| Q2 2026 | $2B | +29% |
| Q1 2026 | $916M | -1.8% |
| Q4 2025 | $2.6B | +22% |
| Q3 2025 | $2.3B | +6.6% |
| Q2 2025 | $1.5B | +8.3% |
| Q1 2025 | $933M | +49% |
| Q4 2024 | $2.1B | -5.9% |
ABT's free cash flow has been positive every quarter for seven years: $6.8B over the past year, down 2.3% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ABT on cash flow, with more consistent year-over-year improvement.
ABT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -5.1M shares |
| 1 year | -0.7% | -11.5M shares |
| 3 years | -0.6% | -10.4M shares |
| 5 years | -2.9% | -51.1M shares |
| Available history | -2.4% | -43.1M shares |
ABT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11M |
| Q2 2026 | $1B |
| Q1 2026 | $180M |
| Q4 2025 | $302M |
| Q3 2025 | $305M |
| Q2 2025 | $6M |
| Q1 2025 | $280M |
| Q4 2024 | $315M |
ABT spent $1.5B buying back its own shares over the past year, up 70% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ABT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.6x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.6x | Very low |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.7x | Very low |
ABT's net debt is about 2.6 years of its operating earnings (EBITDA), up from less than a year a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ABT on leverage, with a lower net debt burden relative to earnings.
ABT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.0 | Neutral |
| Stochastic | 57.1 | Neutral |
ABT's weekly RSI is 54 (neutral) and its Stochastic is 57 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ABT PE vs Healthcare Sector
| Metric | ABT | Sector median | Relative |
|---|---|---|---|
| PE | 40x | 26x | 55% above |
| PE % | 81 | 29 | 52 pts above |
ABT is trading at 40x earnings, a 55% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ABT on valuation relative to its sector.
ABT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $103.8 | 3.3% above |
| 20 week MA | $104.5 | 2.6% above |
| 50 week MA | $104.9 | 2.3% above |
| 100 week MA | $117.0 | 8.4% below |
| 200 week MA | $112.4 | 4.6% below |
ABT has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 4.6% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ABT on trend strength, trading above more of its moving averages.
ABT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $87.4 | $108.4 | +24% |
| 2021 | $108.4 | $139.2 | +28% |
| 2022 | $139.2 | $108.2 | -22% |
| 2023 | $108.2 | $110.1 | +1.7% |
| 2024 | $110.1 | $115.0 | +4.5% |
| 2025 | $115.0 | $124.8 | +8.6% |
| 2026 YTD | $124.8 | $107.3 | -14% |
ABT has finished higher in five of the last six years. It's down 14% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ABT on returns for 2026, with the stronger performance.